LRRK2 and Parkinson disease: However, because the vast majority of LRRK2 PD patients are heterozygous, carrying only one copy of the pathogenic allele, this patient population presents an excellent opportunity for a precision medicine approach to specifically target pathogenic kinase activity, while preserving the normal LRRK2 function of the healthy allele with a G2019S selective inhibitor.